Evaluating Combined Treatment Strategies to Reduce HIV Reservoirs and Achieve Sustained Remission Without Antiretroviral Therapy
Led by Federal University of São Paulo · Updated on 2026-08-19
70
Participants Needed
1
Research Sites
65 weeks
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating combined strategies to reduce the HIV proviral reservoir size in people with HIV who have been on suppressive antiretroviral treatment. The study aims to achieve sustained HIV remission without the need for ongoing antiretroviral medications by testing a combination of treatments that target viral latency and infected cells. This is a Phase 2 clinical trial supported by the Federal University of So Paulo.
Participants will be randomly assigned to one of two groups. One group will receive no further intervention and continue their current treatment. The other group will undergo intensified antiretroviral therapy with dolutegravir and maraviroc, along with additional treatments including a histone deacetylase inhibitor nicotinamide for 48 weeks, gold salt auranofin for the last 24 weeks, and a personalized dendritic cell vaccine. This combination aims to disrupt viral latency and reduce the HIV reservoir.
During the study, participants will be closely monitored with regular measurements of HIV viral load, total and episomal HIV DNA, and cell-associated HIV RNA in blood cells over baseline and several weeks up to 36 months after stopping antiretroviral treatment. Additional assessments include lymphoid tissue biopsies and immune cell activation markers. The research team will also track plasma cytokine levels and bacterial translocation markers. These evaluations will help understand the effects of the interventions and treatment interruption on HIV reservoirs and immune health.
CONDITIONS
Brief Title
Multi Interventional Approaches to Mitigate HIV Reservoirs for the Sustained HIV Remission Without Antiretrovirals
Research Team
R
Ricardo S Diaz, M.D.; PhD
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match. Sign up to get personalized trial recommendations delivered to your inbox.
Conselho Nacional de Desenvolvimento Científico e Tecnológico
Collaborating Sponsor
Who Can Participate
Age: 18Years - 65Years
All Genders
Eligibility Criteria
You may qualify if you...
Age between 18 and 65 years
Documented HIV-1 infection
On highly active antiretroviral therapy (HAART) for at least 2 years with no changes in the last 24 weeks
HIV viral load under 50 copies/mL with no two consecutive readings above 50 copies/mL in the past 2 years
CD4 cell count nadir greater than 350 cells/mm3
Current CD4 cell count greater than 500 cells/mm3
Presence of R5 HIV-1 strain at screening as defined by proviral DNA genotropism
Signed informed consent form
You will not qualify if you...
Evidence of active AIDS-defining condition
Significant acute medical illness in the past 8 weeks
Women who are pregnant or breastfeeding
Use of systemic cytotoxic chemotherapy, investigational agents, or immunomodulators within 90 days before enrollment
Use of coumadin, warfarin, or similar anticoagulants within 90 days before enrollment
Use of medications associated with QT interval effects
Use of HDAC inhibitor-like compounds such as valproic acid or nicotinamide within the last 30 days without a 30-day washout
Known hypersensitivity to gold salt, nicotinamide, or their analogs
Hepatitis B or C infection
Renal insufficiency with creatinine clearance below 60 mL/min
Laboratory abnormalities grade 3 or 4 except for specified exceptions
Any condition that may compromise safety or adherence to the trial protocol
Your Study Journey
Screening
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
Treatment
Duration - 48 weeks
Participants are randomly assigned to either continue their current antiretroviral therapy without additional intervention or receive intensified antiretroviral treatment combined with other therapies including nicotinamide, auranofin, and a dendritic cell vaccine over 48 weeks.
Regular visits during treatment and follow-up
Follow-up
Duration - Up to 36 months after treatment
Participants are closely monitored with regular measurements of viral load, HIV DNA and RNA, immune cell counts, and other markers for up to 36 months after stopping antiretroviral therapy to assess sustained remission.
Visits every 3 weeks after antiretroviral treatment interruption
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Similar Trials
Improving HIV Testing in European Hospitals by Introducing Dedicated HIV Teams A Multicenter Study Across Ten Countries
Pilot Study to Prevent Frailty in People Living with HIV Aged 65 to 74
Remote Tai ChiQigong vs Health Education for Depression in Older Adults Living with HIV A Randomized Clinical Trial
Reducing Chlamydia Disparities in Black Youth Through Community-Based Testing and Treatment in the Deep South
Evaluating Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adults Without HIV Using Multiple Doses and Routes
Randomized Trial to Improve Muscle Health and Reduce Fat in Veterans with HIV and Obesity
Phase 1 Study of GRAdHIVNE1 Vaccine for Adults With and Without HIV in Southern Africa
Evaluation of DV700P-RNA and DV701B1.1-RNA Vaccines with Antiretroviral Treatment Interruption in Adults Living with HIV
Improving Cervical Cancer Screening and Treatment for Women Living with HIV in Nigeria Using Enhanced Implementation Strategies
Studying Immune and Viral Changes During Early HIV Infection
Using Combination Anti-Retroviral Therapy
A Long-Term Observational Study
Have more questions? Get in touch with our team for quick support
Published Research Related To This Trial
Immunogenicity of personalized dendritic-cell therapy in HIV-1 infected individuals under suppressive antiretroviral treatment: interim analysis from a phase II clinical trial.
Marcella Vassão de Almeida Baptista, Laís Teodoro da Silva, Sadia Samer...